Sapient’s Dr. Mo Jain discusses the role next-generation mass spectrometry will play in the evolution of precision drug development.
Sapient’s Dr. Mo Jain discusses the role next-generation mass spectrometry will play in the evolution of precision drug development.
Population health studies finally have an efficient, scalable approach to ‘go beyond the genome’ in biomarker discovery.
Dr. Jain shares how nontargeted biomarker discovery provides a nontraditional path to advance drug development.
Why data transparency is imperative to ensure the accuracy and reproducibility of findings that inform drug development.
